Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
Le Lézard

Digi Power X Strengthens Balance Sheet to Support 2026 AI Infrastructure Development Plan

Digi Power X Inc. ("Digi Power X" or the "Company") , an innovative energy infrastructure company, today announced a significant strengthening of its balance sheet and liquidity position to support ...

Franco-Nevada Reports Record Q3 2025 Results

Franco-Nevada's record quarterly results benefited from a combination of higher gold prices, strong operations, new acquisitions and the sale of Cobre Panama copper concentrate stockpiles. Our ...
Le Lézard

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Tharimmune, Inc. ("Tharimmune" or the "Company") today announced that it has entered into subscription agreements with certain institutional and accredited investors in a private placement offering ...

Castle Biosciences Reports Third Quarter 2025 Results

Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) ...

Perfect Corp. Reports Unaudited Financial Results for the Three Months and the Nine Months Ended September 30, 2025

Perfect Corp. (NYSE: PERF) ("Perfect" or the "Company"), a leading artificial intelligence ("AI") company offering AI and augmented reality ("AR") powered solutions to beauty, fashion, photo and video ...